Patents Assigned to MC2 Therapeutics Limited
  • Topical composition
    Patent number: 11744799
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, wherein the polyaphron dispersion comprises a continuous phase, a discontinuous phase and crisaborole.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: September 5, 2023
    Assignee: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou
  • TOPICAL COMPOSITION
    Publication number: 20230226077
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
    Type: Application
    Filed: March 20, 2023
    Publication date: July 20, 2023
    Applicant: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou, Stephen LENON, Morten PRAESTEGAARD
  • Topical composition
    Patent number: 11696919
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: July 11, 2023
    Assignee: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou, Stephen Lenon, Morten Praestegaard
  • Topical composition
    Patent number: 11638711
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: May 2, 2023
    Assignee: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou, Stephen Lenon, Morten Praestegaard
  • Topical composition comprising tacrolimus
    Patent number: 11458125
    Abstract: The present invention relates to a composition for topical application comprising: a first discontinuous phase comprising a first oil and tacrolimus; a second discontinuous phase comprising a second oil; and a continuous aqueous phase; wherein the first oil is different from the second oil.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: October 4, 2022
    Assignee: MC2 Therapeutics Limited
    Inventor: Nigel Crutchley
  • TOPICAL COMPOSITION COMPRISING TACROLIMUS
    Publication number: 20220273627
    Abstract: The present invention relates to a composition for topical application comprising: a first discontinuous phase comprising a first oil and tacrolimus; a second discontinuous phase comprising a second oil; and a continuous aqueous phase; wherein the first oil is different from the second oil.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 1, 2022
    Applicant: MC2 Therapeutics Limited
    Inventor: Nigel CRUTCHLEY
  • TOPICAL COMPSITION
    Publication number: 20210275554
    Abstract: The present invention relates to a composition for topical application comprising a continuous aqueous phase, a discontinuous liquid oil phase, and crisaborole.
    Type: Application
    Filed: July 31, 2018
    Publication date: September 9, 2021
    Applicant: MC2 Therapeutics Limited
    Inventor: Nigel CRUTCHLEY
  • Topical composition
    Patent number: 11065195
    Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: July 20, 2021
    Assignee: MC2 Therapeutics Limited
    Inventors: Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
  • TOPICAL COMPOSITION
    Publication number: 20210015831
    Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
    Type: Application
    Filed: March 18, 2019
    Publication date: January 21, 2021
    Applicant: MC2 Therapeutics Limited
    Inventors: Nigel Crutchley, Michelle Georgiou, Stephen LENON, Morten PRAESTEGAARD